Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

Abstract: The invention relates to compositions and methods for treating an acne. In one embodiment, the invention relates to the use of an RNA inhibitor to treat an acne.

Abstract: Various aspects of the invention relate to compositions comprising polycytotoxic T cells. Some aspects relate to methods for obtaining a composition comprising polycytotoxic T cells. Some aspects relate to methods of administering a composition comprising polycytotoxic T cells to a subject. Some aspects relate to methods for monitoring an immune response in a subject, comprising determining the concentration of polycytotoxic T cells in the blood of the subject. Some aspects relate to methods for treating a condition or disease in a subject, comprising administering to the subject a composition comprising an antibody, or an antigen-binding portion thereof, that specifically binds to a protein expressed by a polycytotoxic T cell.

Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

Abstract: In certain aspects, the disclosure relates to compositions and methods relating to mutant bacteriophage that target Propionibacterium acnes. In certain aspects, compositions and methods described herein are useful for the treatment of acne.

Abstract: Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

Abstract: In some aspects, the invention relates to a transmembrane protein comprising an extracellular domain that may be cleaved from a transmembrane domain by a protease. The extracellular domain may be the extracellular domain of an antigen-presenting protein, such as CD1a.

Abstract: Various aspects of the invention relate to compositions comprising polycytotoxic T cells. Some aspects relate to methods for obtaining a composition comprising polycytotoxic T cells. Some aspects relate to methods of administering a composition comprising polycytotoxic T cells to a subject. Some aspects relate to methods for monitoring an immune response in a subject, comprising determining the concentration of polycytotoxic T cells in the blood of the subject. Some aspects relate to methods for treating a condition or disease in a subject, comprising administering to the subject a composition comprising an antibody, or an antigen-binding portion thereof, that specifically binds to a protein expressed by a polycytotoxic T cell.

Abstract: Certain aspects of the invention relate to methods for preventing or treating a skin condition in a subject, comprising administering a composition comprising a lysterase to the subject. Some aspects of the invention relate to pharmaceutical compositions comprising a lysterase. Some aspects of the invention relate to methods for producing a pharmaceutical composition, comprising expressing a lysterase in a recombinant cell and purifying the lysterase.

Abstract: Granulysin peptides are small antimicrobial agents with potent activity against bacteria and inflammation. A pharmaceutical composition comprising granulysin peptides as an active agent is administered therapeutically to a patient suffering from a microbial infection.

Abstract: Methods for inducing interleukin-12 production and inducing a type 1/Th1 T cell response in a subject, thereby stimulating cell-mediated immunity for prevention or treatment of pathogen infections or treatment of a interferon (-sensitive tumor, are provided. Compounds effective in the above-described methods include a lipopeptide having an N-terminal ester- or amide-linked fatty acyl group and are administered in an amount effective to induce interleukin-12 and to induce the type 1/Th1 T-cell response. Preferably, the subject is a human patient, and the lipopeptide is an N-terminal moiety of a 19 kDa or a 38 kDa lipoprotein of Mycobacterium tuberculosis.

Abstract: The T cell activation marker, granulysin, is demonstrated to be an effective antimicrobial agent. It is used in vitro and in vivo to reduce the population of viable cells in a microbial population. Of particular interest is the use of the active fragment of human granulysin, or modified forms thereof, to treat bacterial infections.

Abstract: The T cell activation marker, granulysin, is demonstrated to be an effective antimicrobial agent. It is used in vitro and in vivo to reduce the population of viable cells in a microbial population. Of particular interest is the use of the active fragment of human granulysin, or modified forms thereof, to treat bacterial infections.

Abstract: The present invention is based on the observation that CD1 functions to present foreign and autoimmune antigens to a select subpopulation of T-cells. Based on this observation, the present invention provides methods for detecting the presence of a CD1-presented antigen in a sample, methods for purifying CD1-presented antigens, vaccines containing CD1-presented antigens, methods of blocking CD1 antigen presentation, methods of identifying and/or isolating CD1 blocking agents, methods of inducing CD1 expression, and T-cell lines for use in the methods disclosed herein. The CD1-presented antigens of the invention, unlike MHC-presented antigens, are non-polypeptide hydrophobic antigens. In particular, a CD1-presented antigen isolated from several mycobacterial species is a lipoarabinomannan (LAM).